Friday, Mylan's shareholders will vote on whether the company should move ahead with its hostile bid for Perrigo. But Teva won't be among them, despite the fact that it built up a 4.61% Mylan stake when it was trying to buy the company earlier this year.
Serial buyer Allergan is getting ready to head back to the bargaining table, and there's plenty of buzz about who its next target will be. Who should it be, though, as far as FiercePharma readers are concerned? That's the question we posed last Tuesday, and since then, more than 500 of you have weighed in.
There are just three days left until Mylan's shareholders decide whether the company should push forward with its hostile pursuit of Perrigo. And just in case they do, Perrigo is making sure its own shareholders are ready to shoot it down.
Bill Ackman's relationship with Valeant has paid off big-time since the hedge fund manager first teamed up with the Canadian pharma on its hostile pursuit of Allergan. And this time, it's an investment in Sprout Pharmaceuticals--Valeant's latest pickup--that's bringing in the bucks.
Rare disease biotech Raptor Pharmaceutical signed a deal to pay up to $418 million to Tripex Pharmaceuticals in exchange for an inhaled treatment for cystic fibrosis.
Novartis is paying GlaxoSmithKline as much as $1 billion for the rights to a mid-stage multiple sclerosis treatment, betting it can develop an heir to the blockbuster Gilenya, soon to lose patent protection.
Roche has been hot on the dealmaking trail this past year, snatching up smaller companies to boost its portfolio. In its latest round of M&A, the diagnostics giant is acquiring Kapa Biosystems, getting its hands on the company's next-generation sequencing (NGS) products to further build out its offerings.
Concept Life Sciences, a CRO pieced together through a string of acquisitions, has inked a deal to acquire a toxicology-focused contractor, looking to expand its palate of drug development services.
That didn't take long. Just one day after Sprout Pharmaceuticals won a controversial FDA approval for new female libido drug Addyi (flibanserin), serial buyer Valeant has agreed to buy the company.
A little more than a day after little Sprout Pharmaceuticals won a controversial FDA approval to market Addyi (flibanserin) as a new drug that can help inspire sexual desire among women, Valeant Pharmaceuticals announced a deal to acquire the one-drug company in a $1 billion buyout.